Private equity Strategy

Our flagship private equity strategy, Nexus, invests in privately held breakthrough biomedical technology companies at all stages, from seed to crossover.  

We focus on companies developing drugs, devices, diagnostics, and data-driven insights in which we have conviction on both the scientific and clinical value propositions as well as the business and financial value propositions.